Kodiak Sciences Consensus Price Target Increased by 65.16% to $117.50
The average one-year price target for Kodiak Sciences (NASDAQGM:KOD) (BMV:KOD) has been revised to $117.50 / share. This is an increase of 65.16% from the prior estimate of $71.14 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation orinvestment adviceby Fintel. The latest targets range from a low of $96.96 to a high of $152.25 / share. The average price target represents an increase of 19.34% from the latest reported closing price of $98.46 / share on October 1, 2026.
Kodiak Sciences Inc. is a US-based biotechnology company focused on developing innovative therapeutics for chronic, high-prevalence retinal diseases. Its project portfolio includes the ABC Platform and KSI-301, an antibody biopolymer conjugate in development for wet age-related macular degeneration and diabetic eye diseases. For context, the company reported its latest earnings on August 13, 2026, with an actual EPS of -1.05 compared to an estimated EPS of -0.9656, on actual and estimated revenues of $0.00. Additionally, the company's stock price changed +196.39% over one week from a baseline close of $33.22 on September 24, 2026, and changed +165.68% over one month from a baseline close of $37.06 on September 1, 2026.
The current mean target of $117.50, as of the data date of September 29, 2026, is also recorded in the target history on October 2, 2026. This is an increase from the mean target of $71.14 recorded on September 15, 2026, and August 28, 2026, and $66.04 on August 5, 2026. The observed twelve-month high mean target is $117.50 on October 2, 2026, and the observed twelve-month low mean target is $12.65 on November 9, 2025. The target change since the 90-day baseline date of June 30, 2026, is +80.00%.
Recent analyst actions include HC Wainwright & Co., UBS, and LifeSci Capital maintaining Buy or Outperform ratings on September 28, 2026, while Goldman Sachs reiterated a Neutral rating on September 24, 2026. The recommendation trend for September 1, 2026, shows 2 strong buy, 7 buy, and 1 hold recommendations, which is unchanged from the August 1, 2026, period. Within the broader Biotechnology sub-industry, 14 companies are covered, with 3 experiencing raised targets, 2 lowered, and 9 unchanged. The sub-industry median revision percent is 0.00%, with a median implied change percent of +203.15%.
Among its industry peers, target revisions remained mostly flat, though some companies show significant implied upside potential based on their latest closing prices.
| Company name | Target revision | Implied change |
|---|---|---|
| Ceryvyn Therapeutics | 0.00% | — |
| Outlook Therapeutics | +2.55% | +791.39% |
| Ocular Therapeutix | 0.00% | +273.96% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.